Roche To Work With UK’s NICE Following Blow For Perjeta
Executive Summary
While the National Institute for Health and Care Excellence has already backed Perjeta for certain indications, its new draft guidance has advised against NHS England using the drug after surgery for early breast cancer.
You may also be interested in...
Bruised Roche Wins Another UK Perjeta Round With Price Cut
In the latest round of what appears to have been a bruising set of price negotiations for Roche, the UK’s cost effectiveness agency NICE has recommended Perjeta in another breast cancer setting.
New EU Approvals
The Pink Sheet's list of EU centralized approvals of new active substances has been updated to add two new products, including Ryzneuta, Evive Biotechnology's treatment for chemotherapy-induced neutropenia.
Outlook Turns To Marketing Strategy After Scoring EU First For Ophthalmic Bevacizumab
Outlook Therapeutics’ intravitreally injected Lytenava has won the thumbs up from the European Medicines Agency. The company is assessing both direct commercialization of the product and partnering in Europe on a country-by-country basis.